1st Department of Cardiology, University of Medical Sciences, Poznan, Poland. Email:
1st Department of Cardiology, University of Medical Sciences, Poznan, Poland.
Cardiovasc J Afr. 2021;32(6):339-342. doi: 10.5830/CVJA-2020-058. Epub 2021 Jan 15.
Levosimendan was developed as a treatment for acute decompensation of severe heart failure (HF). Its use has evolved during recent years, and new HF treatment strategies in different settings have been developed. This case series aimed to show indications for the use of levosimendan and to discuss the treatment response in various settings. Repetitive levosimendan infusions were found to be safe and effective. They seemed to prolong the time of clinical stability, although they did not alter the eventual natural history of HF, with increasing frequency of hospitalisations and rising natriuretic peptide levels.
左西孟旦被开发用于治疗严重心力衰竭（HF）的急性失代偿。近年来，它的应用得到了发展，不同情况下的新 HF 治疗策略也得到了发展。本病例系列旨在展示左西孟旦的应用指征，并讨论不同情况下的治疗反应。重复输注左西孟旦被发现是安全有效的。它们似乎延长了临床稳定的时间，尽管它们并没有改变 HF 的最终自然病程，住院频率增加，利钠肽水平升高。
